tricine

Tricin as a potential enhancer for the treatment of cisplatin-based skin cancer
Tricin as a potential enhancer for the treatment of cisplatin-based skin cancer 585 409 Guillem Cebrian

At the end of December 2019, we talked about the effectiveness of trichina as an adjuvant of cisplatin in treatment. Squamous cell carcinoma is the second most common type of skin cancer. It causes the abnormal growth of squamous cells in the epidermis and represents 20-25% of all skin cancers in Spain. This study led by an I3PT team, led by Sílvia Gil, in close collaboration with…

read more
Privacy preferences

When you visit our website, your browser may store information about specific services, usually in the form of cookies. Here you can change your privacy preferences. Please note that blocking certain types of cookies may affect your experience on our website and the services we offer.

Enable / disable Google Analytics tracking code
Enable / disable Google Fonts
Turn Google Maps on / off
Enable / disable embedded videos
This website uses cookies, mainly from third party services. You can edit your privacy preferences and / or accept the use of cookies.